文献速递血液透析通路慢性静脉疾病

血液透析患者锁骨下静脉胸廓出口狭窄行第一肋切除联合血管内治疗的长期结果与生存

Long-term results and patient survival after first rib resection and endovascular treatment in hemodialysis patients with subclavian vein stenosis at the thoracic outlet.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-05-18

本研究回顾性分析了15例因锁骨下静脉胸廓出口狭窄而接受第一肋切除联合血管内治疗的血液透析患者,平均随访35.13个月,无并发症发生,二次通畅率100%,中位生存期69.3个月,表明该策略安全有效且能维持透析通路功能。

要点

  • 第一肋切除联合血管内治疗可安全用于透析患者锁骨下静脉胸廓出口狭窄,无并发症。
  • 术后二次通畅率100%,但平均需4.6次血管内干预,常需定期随访。
  • 中位生存期69.3个月,提示积极维持通路功能具有临床价值。

核心结论

  • 对于因锁骨下静脉胸廓出口狭窄导致透析通路受威胁的症状性血液透析患者,第一肋切除后行血管内治疗安全成功,无并发症,随访期间维持了透析通路功能。
  • 尽管需要多次二次干预,但可获得良好的二次通畅率和长期临床成功,中位生存期69.3个月支持积极维持通路功能。

研究设计与样本

  • 回顾性综述,纳入2013年至2021年1月连续15例接受第一肋切除联合血管内治疗的血液透析合并锁骨下静脉狭窄患者。
  • 诊断经超声和静脉造影确认,骨减压采用经腋窝或锁骨下第一肋切除。

主要发现

  • 15例中女10例、男5例,平均年龄56.4岁(范围30-82岁),既往透析平均5.4年(范围1-13年)。
  • 14例存在功能通路和严重手臂水肿,9例(60%)锁骨下静脉闭塞者在骨减压前接受静脉再通。
  • 5例行经腋窝、10例行锁骨下第一肋切除;9例同期行静脉支架,6例4周内支架,1例13个月支架;8例用覆膜支架,7例用裸金属支架。
  • 术后平均住院2.6天(范围1-8天),无并发症;平均随访35.13个月(范围4-86个月)。
  • 无后续干预生存率10.5个月时为50%,平均每患者血管内操作4.6次,10例随访期间需通路手术,二次通畅率100%,中位生存期69.3个月。

临床怎么用

  • 对于透析患者锁骨下静脉胸廓出口狭窄且血管内治疗无效时,可考虑第一肋切除联合血管内治疗以挽救通路。
  • 术后需定期随访并准备多次二次干预以维持通路功能。

局限性

  • 回顾性单中心小样本研究(15例),无对照组,结果需谨慎推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hemodialysis patients with upper extremity vascular access and subclavian vein stenosis at the thoracic outlet can present with significant arm edema and threatened dialysis access that is frequently refractory to endovascular therapy without bone decompression. We have presented our long-term results of first rib resection, followed by endovascular therapy. METHODS: We performed a retrospective review of 15 consecutive hemodialysis patients with subclavian vein stenosis treated with first rib resection and endovascular therapy from 2013 to January 2021. The diagnosis was confirmed by ultrasound and venography. Bone decompression was performed with transaxillary or infraclavicular rib resection. RESULTS: During the study period, we treated 1440 unique dialysis patients. Of these 1440 patients, 346 had undergone subclavian vein angioplasty. Of the 346 patients, 15 had undergone first rib resection and were the subject of the present report. Of the 15 patients, 10 were women and 5 were men. Their mean age was 56.4 years (range, 30-82 years). The most commonly associated medical conditions were hypertension and diabetes. The mean previous hemodialysis duration was 5.4 years (range, 1-13 years). Fourteen patients had preexisting functioning access and severe arm edema. Nine patients (60%) with subclavian vein occlusion had undergone vein recanalization before the bone decompression procedure. Of the 15 patients, 5 had undergone transaxillary and 10 had undergone infraclavicular first rib resection. In addition, nine patients had undergone simultaneous vein stenting, six had undergone vein stenting within 4 weeks, and one had undergone stenting at 13 months. A stent-graft was used in eight patients and a bare metal stent was used in seven. All preexisting dialysis access sites were used the day after the procedure. The average postoperative stay was 2.6 days (range, 1-8 days). No complications developed. The average follow-up was 35.13 months (range, 4-86 months). The freedom from any subsequent intervention was 50% at 10.5 months. The average number of endovascular procedures per patient during follow-up was 4.6. Ten patients had required access surgery during follow-up. Secondary patency was 100%. The median patient survival was 69.3 months. CONCLUSIONS: Symptomatic hemodialysis patients with threatened vascular access caused by subclavian vein stenosis at the thoracic outlet were safely and successfully treated with first rib resection, followed by endovascular techniques. The procedure resulted in no morbidity and preserved dialysis access function in all patients during follow-up. Our experience has confirmed that excellent secondary patency and long-term clinical success can be obtained with regular follow-up, although with multiple secondary interventions. The median survival of 69 months after the procedure suggests it is worthwhile to expend this effort to maintain the hemodialysis access function of these patients.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Uceda PV, Feldtman RW, Ahn SS, et al. Long-term results and patient survival after first rib resection and endovascular treatment in hemodialysis patients with subclavian vein stenosis at the thoracic outlet. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34020110. doi:10.1016/j.jvsv.2021.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。